ZyVersa Therapeutics, Inc. (ZVSA) P/E Ratio History
Historical price-to-earnings valuation from 2026 to 2026
Loading P/E history...
ZVSA Valuation Context
How does the current P/E compare to historical and market benchmarks?
P/E Ratio Analysis
As of May 15, 2026, ZyVersa Therapeutics, Inc. (ZVSA) trades at a price-to-earnings ratio of -0.0x, with a stock price of $0.20 and trailing twelve-month earnings per share of $-0.00.
Compared to the Healthcare sector median P/E of 21.7x, ZVSA trades at a 100% discount to its sector peers. The sector includes 238 companies with P/E ratios ranging from 0.0x to 169.5x.
Relative to the broader market, ZVSA trades at a notable discount to the S&P 500 median P/E of 24.7x. Investors should consider the company's growth prospects, competitive position, and earnings quality when evaluating whether the current valuation is justified.
For a comprehensive intrinsic value estimate using discounted cash flow analysis, see our ZVSA DCF Valuation Calculator →
Note: P/E ratio is just one valuation metric. It does not account for balance sheet strength, cash flow quality, or growth sustainability. Always conduct comprehensive due diligence before making investment decisions.
ZVSA P/E vs Peers
P/E ratio compared to closely matched public peers
| Company | Market Cap | P/E Ratio | PEG Ratio | EPS Growth (1Y) |
|---|---|---|---|---|
| $8B | 27.0Lowest | 1.18Best | -25% | |
| $9B | 46.2 | - | +128%Best |
Peers sorted by market capitalization. P/E below peers may indicate undervaluation or lower growth expectations. Consider PEG ratio for growth-adjusted comparison.
See ZVSA's True Return
Price is only half the story. See total return with reinvested dividends.
Launch CalculatorIs ZVSA Undervalued?
DCF intrinsic value, peer multiples, and analyst estimates — see what the stock is really worth.
View ValuationCompare ZVSA vs DBVT
Side-by-side business, growth, and profitability comparison vs DBV Technologies S.A..
Start ComparisonZVSA — Frequently Asked Questions
Quick answers to the most common questions about buying ZVSA stock.
Is ZVSA stock overvalued or undervalued?
ZVSA current P/E: -0.0x. 5-year average P/E: N/A. Percentile: N/A.
How does ZVSA's valuation compare to peers?
ZyVersa Therapeutics, Inc. P/E of -0.0x compares to sector median of 21.7x. Sector comparison provides relative valuation context.
What is ZVSA's PEG ratio?
ZVSA PEG ratio is N/A. Above 2.0 indicates premium valuation relative to growth rate. Historical P/E data spans 2026-2026.